Express Scripts Says Still Reviewing Gilead Drugs

Gilead Sciences Inc.’s top-selling hepatitis C drug, Harvoni, has been removed from Express Scripts Holding Co.’s list of excluded drugs for next year and will be reviewed for potential coverage, according to the pharmacy benefits manager.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.